AbbVie has announced the initiation of Phase 3 clinical trials for its novel botulinum toxin type E (BoNT/E) candidate, which demonstrated onset of action within 24 hours in Phase 2 studies — dramatically faster than the 3-7 day onset typical of current botulinum toxin type A products including Botox, Dysport, and Xeomin. The Phase 3 program, called SWIFT, will enroll approximately 1,800 participants across 80 sites and evaluate the treatment of moderate to severe glabellar lines and lateral canthal lines.
The rapid onset advantage of BoNT/E addresses one of the primary limitations of current neurotoxin treatments. Many patients, particularly those seeking cosmetic treatment before events or occasions, are frustrated by the multi-day wait for results. Phase 2 data showed that 78% of participants had visible improvement within 24 hours of BoNT/E injection, compared to approximately 10% with traditional BoNT/A products. The ultra-rapid onset could enable same-day ‘touch-up’ appointments and allow injectors to assess results and make adjustments in real time.
However, BoNT/E has a notably shorter duration of action compared to BoNT/A — approximately 4-6 weeks versus 3-4 months. AbbVie is positioning this as a feature rather than a limitation, arguing that shorter duration appeals to first-time neurotoxin users who are hesitant to commit to months of altered facial movement, and could serve as a ‘trial’ experience for neurotoxin-curious consumers. The company is also exploring higher-dose formulations that may extend duration to 8-10 weeks while maintaining rapid onset.
The aesthetics industry is closely watching the SWIFT program, as a successful Phase 3 could create an entirely new market segment. Analysts at JPMorgan estimate BoNT/E could represent a $2-3 billion annual opportunity by 2032, primarily as a complement to rather than replacement for existing BoNT/A products. AbbVie expects top-line Phase 3 results in the first half of 2027, with a potential FDA submission in late 2027.